OmniAsset
Get app

OmniAsset › Mutual funds › Nippon India Pharma Fund

Nippon India Pharma Fund

Sectoral / Thematic fund benchmarked to BSE Healthcare TRI. Every figure below is read from one dated snapshot; what the snapshot cannot prove is left out, never estimated.

Latest NAV2 Sep 2026646.8638
CategorySectoral / Thematic
PlanDirect · Growth
Launched10 May 2004
Risk labelthe scheme's own riskometerVery High
Legal benchmarkSEBI Tier-1BSE Healthcare TRI
Expense ratiodirect plan, a year · stated maximum, from the scheme document0.99%
AUM₹2,251 Cr
Growth of ₹10,000₹19,0432 Sep 2021 to 2 Sep 2026
₹19,242₹16,464₹13,687₹10,910₹8,133Sep 2021Nov 2022Mar 2024Jun 2025Sep 2026
₹19,043 (+13.8% a year) Nippon India Pharma Fund

Performance (trailing, annualised)

1Y annualised14.11%
3Y annualised19.66%
5Y annualised13.75%
10Y annualised15.86%

Point-to-point from the fund's own published NAV; a period the history does not span is left out.

SIP returns

SIP 1Y (₹10,000 a month)invested ₹1,20,000 → worth ₹1,33,98022.20%
SIP 3Y (₹10,000 a month)invested ₹3,60,000 → worth ₹4,48,17114.75%
SIP 5Y (₹10,000 a month)invested ₹6,00,000 → worth ₹9,42,48318.11%

₹10,000 on the first of every month, valued at the latest NAV, as an annualised rate (XIRR).

Calendar years

Calendar 202125.12%
Calendar 2022-9.06%
Calendar 202340.36%
Calendar 202435.26%
Calendar 2025-2.46%

Rolling returns

Rolling 1Y · average653 windows since 6 Jan 201420.14%
Rolling 1Y · median13.32%
Rolling 1Y · worst window-14.41%
Rolling 1Y · best window84.70%
Rolling 1Y · windows positive76%
Rolling 3Y · average551 windows since 4 Jan 201617.15%
Rolling 3Y · median20.08%
Rolling 3Y · worst window-1.11%
Rolling 3Y · best window32.06%
Rolling 3Y · windows positive98%
Rolling 5Y · average448 windows since 3 Jan 201816.61%
Rolling 5Y · median16.67%
Rolling 5Y · worst window0.48%
Rolling 5Y · best window31.74%
Rolling 5Y · windows positive100%

Every window of that length in the published history, so one lucky start date cannot flatter the fund.

Risk

Volatility (3Y)12.96%
Downside deviation (3Y)8.90%
Maximum drawdown-14.72%

Management

Fund managerSailesh Raj Bhan
Managing since10 Jun 2022

What it holds

SecurityWeight
Sun Pharmaceutical Industries Limited13.3%
Lupin Limited7.2%
Divi's Laboratories Limited6.5%
Cipla Limited6.0%
Apollo Hospitals Enterprise Limited5.3%
Dr. Reddy's Laboratories Limited5.0%
Mankind Pharma Limited3.7%
Sai Life Sciences Limited3.6%
Ajanta Pharma Limited3.4%
Max Healthcare Institute Limited3.1%
SectorWeight
Pharmaceuticals & Biotechnology73.5%
Healthcare Services21.1%
Retailing2.7%

Portfolio disclosed: 97.3% by weight.

Related

Source: the OmniAsset signed reference snapshot, as of 4 Sep 2026. Figures are deterministic; missing data is withheld, never estimated. See methodology and data sources. Not investment advice.

Research this fund and compare it — on your device.

Get OmniAsset on Google Play The mutual fund tracker